Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 21 min ago
PreprintAll rights reservedbioRxiv

CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma

  • C. Custodia
  • R. Cascao
  • E. Paisana
  • D. Picard
  • P. Ruivo
  • T. Rodrigues
  • I. Lourenco
  • S. Nunes
  • N. Qin
  • L. Albuquerque
  • R. Roque
  • J. Miguens
3 more authors
  • M. Remke
  • J. T. Barata
  • C. C. Faria1
  1. 1GIMM - Gulbenkian Institute for Molecular Medicine, Lisboa, Portugal
Read full textPDFDOICite

Related

  1. MiR-532 as a Potential Therapeutic Target and Biomarker: Biological Functions, Molecular Mechanisms, and Clinical Perspectives.
    Leila Mohammadi, Tourandokht Baluchnejadmojarad, Mehrdad Roghani
    Drug design, development and therapyPeer-reviewedCC BY-NCFull textOncologyEurope PMCPMC
  2. Tissue Transglutaminase (TG2) as a Candidate Biomarker and Potential Therapeutic Target in Endometriosis: Functional Evidence from shRNA-Mediated Downregulation of TG2 in Endometrial Mesenchymal Stem Cells.
    İnci Kurt-Celep, Melike Batukan, Fikrettin Şahin +1
    Pharmaceuticals (Basel, Switzerland)Peer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC
  3. Lactate as a predictive biomarker and therapeutic target in cardiopulmonary bypass-associated acute kidney injury
    Dinghao Xue, Mingru Zhang, Xinlu Chang +4
    iSciencePeer-reviewedCC BY 4.0Full textGeneral medicineCell PressCrossrefEurope PMC
  4. ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma
    Xiaoqun Xu, Chaofeng Zhou, Rui Zhang +2
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textOncologyCell PressCrossrefEurope PMC
  5. ARF6: Biomarker, Therapeutic Target, and AI-Driven Precision Management for Type 2 Diabetes with Obesity
    Yangyang Wang, Ye Chen, Huiyan Wang
    MetabolitesPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@misc{custodia2026ccr2,
  title = {{CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma}},
  author = {C. Custodia and R. Cascao and E. Paisana and D. Picard and P. Ruivo and T. Rodrigues and I. Lourenco and S. Nunes and N. Qin and L. Albuquerque and R. Roque and J. Miguens and M. Remke and J. T. Barata and C. C. Faria},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.11.757412},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.11.757412v1},
}
RIS
TY  - UNPB
TI  - CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma
AU  - C. Custodia
AU  - R. Cascao
AU  - E. Paisana
AU  - D. Picard
AU  - P. Ruivo
AU  - T. Rodrigues
AU  - I. Lourenco
AU  - S. Nunes
AU  - N. Qin
AU  - L. Albuquerque
AU  - R. Roque
AU  - J. Miguens
AU  - M. Remke
AU  - J. T. Barata
AU  - C. C. Faria
PY  - 2026
DA  - 2026/10/11
PB  - bioRxiv
DO  - 10.64898/2026.10.11.757412
UR  - https://www.biorxiv.org/content/10.64898/2026.10.11.757412v1
ER  -